Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer

Malignant Neoplasm of Stomach Clinical Trial

Official title:

A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Locally Advanced Gastric Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04345770
• Other study ID #: WuhanZN_HIPEC
• Status: Recruiting
• Phase: Phase 2
• Start date: April 1, 2020
• Est. completion date: May 31, 2025

Study information

• Verified date: April 2020
• Source: Wuhan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal metastasis in locally advanced gastric cancer is not definite. The hypothesis of the trial is that radical gastrectomy combined with HIPEC is superior to only radical gastrectomy in terms of overall survival.

Description:

To determine the efficacy of HIPEC in the treatment of locally advanced gastric cancer, patients are randomized into HIPEC group and control group. In HIPEC group, the patients undergo neoadjuvant chemotherapy followed by radical gastrectomy with D2 lymphadenectomy and HIPEC with paclitaxel and 5-Fu. Patients in the control group just undergo neoadjuvant chemotherapy followed by radical gastrectomy with D2 lymphadenectomy. Patients in both groups receive postoperative chemotherapy (6 circles together with neoadjuvant chemotherapy) and are followed up for 5 years or until death.

The trial is designed as a prospective, randomized, open and parallel group study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: May 31, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histological proved diagnosis of locally advanced gastric cancer.

• No evidence of distant metastases or peritoneal metastases.

• Preoperative examination (CT/MRI) demonstrated resectable gastric cancer with T3-T4 stage.

• Eligible for radical gastrectomy with D2 lymphadenectomy.

• Have not received cytotoxic chemotherapy or radiotherapy.

• Written informed consent is obtained prior to commencement of trial treatment.

Exclusion Criteria:

• Existence of distant metastasis or peritoneal metastasis during surgery (M1).

• Any previous chemotherapy or radiotherapy

• Active systemic infections

• Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.

• Female patients who are pregnant or breast feeding

Related Conditions & MeSH terms

• Malignant Neoplasm of Stomach
• Neoplasms
• Stomach Neoplasms

Intervention

Procedure:
• D2 radical gastrectomy
radical gastrectomy with D2 lymphadenectomy

Drug:
• SOX neoadjuvant or postoperative chemotherapy
Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.

Procedure:
• Hyperthermic intraperitoneal chemotherapy (HIPEC)
Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.

Locations

Country	Name	City	State
China	Wuhan University	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Wuhan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival	From the date of surgery to the date of death or to the end of follow-up	5 years
Secondary	progression-free survival		5 years
Secondary	distant metastasis rate		5 years
Secondary	peritoneal metastasis rate		5 years
Secondary	local recurrence rate		5 years
Secondary	complication rate		5 years